Table 5.
Joint effects of aromatase inhibitor use and tamoxifen use on the risk of meningioma in patients with breast cancer as revealed by the time-dependent regression model.
| Tamoxifen | Aromatase inhibitor | N | Event | Person-years | IR | Adjusted HR‡
(95% CI) |
|---|---|---|---|---|---|---|
| No | No | 26,177 | 27 | 100,922 | 2.68 | 1.00 |
| No | Yes | 4,752 | 8 | 15,631 | 5.12 | 1.21 (0.54, 2.71) |
| Yes | No | 34,815 | 28 | 156,553 | 1.79 | 0.69 (0.40, 1.18) |
| Yes | Yes | 15,627 | 14 | 81,020 | 1.73 | 0.59 (0.31, 1.15) |
CI, confidence interval; HR, hazard ratio; IR, incidence density rates (per 10,000 person-years). ‡Adjusted for age, comorbidity, steroid use, statin use, thiazide diuretics use, breast surgery, radiotherapy, and chemotherapy.